Lavipharm Goodwill
Goodwill of Lavipharm (LAVI.AT) as of Oct 12, 2026.
Get this data via API
Financial Data API
Goodwill
-EUR
Last updated:
Goodwill of Lavipharm is 2026 - EUR. Goodwill of Lavipharm was 2025 - EUR. It decreases by % lower compared to the previous year.
The Lavipharm Goodwill history
3 Years
10 Years
25 Years
Max
Goodwill
Date
Goodwill
Jan 1, 2000
0.00 EUR
Jan 1, 2001
0.00 EUR
Jan 1, 2004
2.60 M EUR
Jan 1, 2009
100,000.00 EUR
Jan 1, 2010
100,000.00 EUR
Jan 1, 2011
100,000.00 EUR
Jan 1, 2012
100,000.00 EUR
| YEAR | Goodwill | YoY |
|---|---|---|
| 100,000.00EUR | 0.00% | |
| 100,000.00EUR | 0.00% | |
| 100,000.00EUR | 0.00% | |
| 100,000.00EUR | -96.15% | |
| 2.60 MEUR | — | |
| 0.00EUR | — | |
| 0.00EUR | — |
Access this data via the Eulerpool API
Lavipharm Stock analysis
What does Lavipharm do? Lavipharm is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Lavipharm stock
On Eulerpool you can find the complete historical development of Goodwill Lavipharm since 2006 – with annual values, charts, and detailed analysis.
Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.
Goodwill's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Lavipharm historically and in real time.
Access this data via the Eulerpool API
Balance Sheet — Lavipharm
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Lavipharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth